蒿甲醚-本芴醇治疗无并发症恶性疟原虫疟疾。
Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.
机构信息
Bernhard Nocht Institute for Tropical Medicine, Tropical Medicine Section, Hamburg, Germany.
出版信息
Ther Clin Risk Manag. 2009;5:805-15. doi: 10.2147/tcrm.s5375. Epub 2009 Oct 12.
Abstract
The World Health Organization strongly recommends artemisinin-based combination therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria cases in endemic areas. Among the combinations of compounds that are available at present, excellent results have been obtained for the artemisinin derivative artemether, in a combination galenic preparation with lumefantrine (artemether-lumefantrine, AL). Here, the pharmacological properties and the therapeutic options of both substances are briefly reviewed and a cursory overview is given on recent trials that have compared the therapeutic effects of AL in the standard 6-dose regimen with other antimalarials and combinations. In order to ensure the most achievable and reliable adherence and compliance of children in the treatment of malaria, a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance to ACT regimens in Asia, however, are alarming.
摘要
世界卫生组织强烈建议在流行地区使用青蒿素为基础的联合疗法（ACT）治疗方案来治疗无并发症的恶性疟原虫疟疾。在目前可获得的化合物组合中，青蒿素衍生物青蒿琥酯与咯萘啶（蒿甲醚-咯萘啶，AL）联合的复方制剂取得了极佳的效果。在此，简要回顾了这两种药物的药理学特性和治疗选择，并简述了最近比较 AL 在标准 6 剂量方案与其他抗疟药和联合用药的治疗效果的试验。为了确保儿童在治疗疟疾时尽可能实现并保持最可靠的服药依从性，现在可以获得 AL 的分散片制剂。然而，最近有报告称亚洲出现了对 ACT 疗法方案的耐药性，这令人担忧。
相似文献
1
Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.蒿甲醚-本芴醇治疗无并发症恶性疟原虫疟疾。
Ther Clin Risk Manag. 2009;5:805-15. doi: 10.2147/tcrm.s5375. Epub 2009 Oct 12.
2
Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.定制蒿甲醚-本芴醇儿科制剂用于治疗恶性疟原虫疟疾。
Antimicrob Agents Chemother. 2015 Aug;59(8):4366-74. doi: 10.1128/AAC.00014-15. Epub 2015 May 26.
3
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.2019 年坦桑尼亚大陆采用青蒿琥酯-咯萘啶治疗无并发症恶性疟原虫疟疾的疗效和安全性。
Malar J. 2024 Apr 9;23(1):101. doi: 10.1186/s12936-024-04931-0.
4
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.三药联合疗法与青蒿素类复方疗法治疗无并发症恶性疟原虫疟疾的比较：一项多中心、开放标签、随机临床试验。
Lancet. 2020 Apr 25;395(10233):1345-1360. doi: 10.1016/S0140-6736(20)30552-3. Epub 2020 Mar 11.
5
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2018.2018 年，在坦桑尼亚大陆使用青蒿琥酯-咯萘啶治疗无并发症恶性疟的疗效和安全性。
Malar J. 2024 Apr 6;23(1):95. doi: 10.1186/s12936-024-04926-x.
6
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India.蒿甲醚-本芴醇治疗印度四个疟疾流行州无并发症恶性疟的疗效。
Malar J. 2021 May 21;20(1):229. doi: 10.1186/s12936-021-03762-7.
7
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.蒿甲醚-本芴醇与青蒿琥酯治疗妊娠期非复杂性恶性疟的随机对照试验。
PLoS Med. 2008 Dec 23;5(12):e253. doi: 10.1371/journal.pmed.0050253.
8
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.青蒿琥酯-甲氟喹与蒿甲醚-本芴醇固定剂量复方制剂治疗撒哈拉以南非洲5岁以下儿童单纯性恶性疟的比较：一项随机、多中心、4期试验
Lancet Infect Dis. 2016 Oct;16(10):1123-1133. doi: 10.1016/S1473-3099(16)30020-2. Epub 2016 Jul 16.
9
Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria.蒿甲醚-本芴醇（六日疗法）治疗非复杂性恶性疟
Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD005564. doi: 10.1002/14651858.CD005564.
10
Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children.儿童用青蒿素为基础的联合疗法制剂治疗儿童无并发症疟疾。
Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD009568. doi: 10.1002/14651858.CD009568.pub2.
引用本文的文献
1
β-Artemether and Lumefantrine Dual Drug Loaded Lipid Nanoparticles: Physicochemical Characterization, Pharmacokinetic Evaluation and Biodistribution Study.载有双药的β-蒿甲醚和本芴醇脂质纳米粒：理化特性、药代动力学评价及生物分布研究
Pharm Nanotechnol. 2022;10(3):210-219. doi: 10.2174/2211738510666220428133532.
2
Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against sporozoites infection in mice.子孢子下的氯氟菲醇化学预防（CPS-LMF）免疫可诱导小鼠针对子孢子感染产生保护性免疫反应。
3 Biotech. 2021 Nov;11(11):465. doi: 10.1007/s13205-021-03022-0. Epub 2021 Oct 19.
3
Effects of lemon decoction on malaria parasite clearance and selected hematological parameters in Plasmodium berghei ANKA infected mice.柠檬煎剂对伯氏疟原虫感染小鼠疟原虫清除和部分血液学参数的影响。
BMC Complement Med Ther. 2020 Jan 30;20(1):24. doi: 10.1186/s12906-020-2820-1.
4
Primaquine treatment and relapse in Plasmodium vivax malaria.间日疟原虫疟疾的伯氨喹治疗与复发
Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18.
5
New insights into the Plasmodium vivax transcriptome using RNA-Seq.利用RNA测序技术对间日疟原虫转录组的新见解。
Sci Rep. 2016 Feb 9;6:20498. doi: 10.1038/srep20498.
6
Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.一种用于肠胃外给药的新型蒿甲醚-本芴醇脂质乳剂增强抗疟活性。
Antimicrob Agents Chemother. 2014 Oct;58(10):5658-65. doi: 10.1128/AAC.01428-13. Epub 2014 Jun 30.
7
Synthesis of five- and six-membered cyclic organic peroxides: Key transformations into peroxide ring-retaining products.五元环和六元环环状有机过氧化物的合成：保留过氧环产物的关键转化。
Beilstein J Org Chem. 2014 Jan 8;10:34-114. doi: 10.3762/bjoc.10.6.
8
Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda.在卢旺达，对孕妇使用蒿甲醚-本芴醇进行了药物警戒监测，直至分娩。
Malar J. 2012 Jul 6;11:225. doi: 10.1186/1475-2875-11-225.
9
Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania.坦桑尼亚医疗机构实施青蒿琥酯-咯萘啶疟疾治疗政策。
Risk Manag Healthc Policy. 2011;4:89-95. doi: 10.2147/RMHP.S23054. Epub 2011 Sep 6.
本文引用的文献
1
Artemisinin-resistant malaria in Asia.亚洲的抗青蒿素疟疾
N Engl J Med. 2009 Jul 30;361(5):540-1. doi: 10.1056/NEJMc0900231.
2
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
3
The global portfolio of new antimalarial medicines under development.正在研发的新型抗疟药物的全球组合。
Clin Pharmacol Ther. 2009 Jun;85(6):584-95. doi: 10.1038/clpt.2009.51. Epub 2009 Apr 29.
4
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.在非洲开展的一项随机多中心试验：固定剂量青蒿琥酯-磺胺多辛-乙胺嘧啶与蒿甲醚-本芴醇治疗非复杂性恶性疟的疗效及安全性比较
Malar J. 2009 Apr 14;8:63. doi: 10.1186/1475-2875-8-63.
5
First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria.日本一名输入性恶性疟原虫疟疾旅行者中出现蒿甲醚-本芴醇治疗失败的首例病例。
Jpn J Infect Dis. 2009 Mar;62(2):139-41.
6
Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions.过期的蒿甲醚-本芴醇固定剂量复方制剂在非受控热带条件下的物理和化学稳定性。
Malar J. 2009 Feb 25;8:33. doi: 10.1186/1475-2875-8-33.
7
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment.在持续使用13年期间，泰国西北边境地区对青蒿琥酯-甲氟喹治疗反应的变化。
PLoS One. 2009;4(2):e4551. doi: 10.1371/journal.pone.0004551. Epub 2009 Feb 23.
8
A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya.蒿甲醚-本芴醇混悬液与蒿甲醚-本芴醇片剂治疗肯尼亚西部儿童单纯性恶性疟原虫疟疾的随机、开放标签、疗效对比试验
Malar J. 2008 Dec 22;7:262. doi: 10.1186/1475-2875-7-262.
9
10
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.RTS,S/AS01E疫苗对5至17月龄儿童疟疾的疗效。
N Engl J Med. 2008 Dec 11;359(24):2521-32. doi: 10.1056/NEJMoa0807381. Epub 2008 Dec 8.
Zotero 插件